Here's Why Radius Health Is Rising Today
After presenting data from a phase 1 study at a medical conference, shares of Radius Health (NASDAQ: RDUS), a commercial-stage biotech focused on osteoporosis and cancer, rose 15% as of 11:15 a.m. EST on Friday.
Radius Health presented data from its phase 1 005 trial at the 2017 San Antonio Breast Cancer Symposium. This study was designed to evaluate a compound called elacestrant (RAD1901) as a potential treatment for estrogen receptor positive (ER+) breast cancer.
This study enrolled 40 patients with advanced breast cancer that had received an average of three prior lines of therapy. Here are the key clinical takeaways from the study:
Source: Fool.com
